IP Library › Granted Patent US 12,590,171
Granted Patent B2
US 12,590,171 · App. 17/753,021 · Granted Mar 31, 2026

Anti-VHH domain antibodies and use thereof

Inventors: Xijian Qin (Nanjing, CN); Liwei Sun (Nanjing, CN); Wanyi Wang (Nanjing, CN); Guangwei Song (Nanjing, CN)
Assignee: Nanjing GenScript Biotech Co., Ltd.
C07K16/42C07K16/2809C12N5/0682C12N15/85C12P21/005G01N33/6854A61K39/00C12N2800/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,590,171
App. No.
17/753,021
Granted
Mar 31, 2026
Kind
B2
Abstract

The invention provides a group of anti-VHH domain antibodies and use thereof. The present invention further provides use of the described antibodies in the development, screening and purification of nano-antibodies, and use of the described antibodies in the field of immunotherapy.

Claims (48)

1 . An antibody or antigen-binding fragment thereof, wherein the antibody contains a heavy chain variable region and a light chain variable region, wherein (A) the heavy chain variable region comprises heavy chain complementarity determining region (HCDR) 1, HCDR2 and HCDR3, and (B) the light chain variable region comprises light chain complementarity determining region (LCDR) 1, LCDR2, and LCDR3, wherein the antibody contains

(1) HCDR1 shown in SEQ ID NO: 14, HCDR2 shown in SEQ ID NO: 29, HCDR3 shown in SEQ ID NO: 44, LCDR1 shown in SEQ ID NO: 59, LCDR2 shown in SEQ ID NO: 74 and LCDR3 shown in SEQ ID NO: 89;

(2) HCDR1 shown in SEQ ID NO: 4, HCDR2 shown in SEQ ID NO: 19, HCDR3 shown in SEQ ID NO: 34, LCDR1 shown in SEQ ID NO: 49, LCDR2 shown in SEQ ID NO: 64 and LCDR3 shown in SEQ ID NO: 79;

(3) HCDR1 shown in SEQ ID NO: 15, HCDR2 shown in SEQ ID NO: 30, HCDR3 shown in SEQ ID NO: 45, LCDR1 shown in SEQ ID NO: 60, LCDR2 shown in SEQ ID NO: 75 and LCDR3 shown in SEQ ID NO: 90;

(4) HCDR1 shown in SEQ ID NO: 1, HCDR2 shown in SEQ ID NO: 16, HCDR3 shown in SEQ ID NO: 31, LCDR1 shown in SEQ ID NO: 46, LCDR2 shown in SEQ ID NO: 61 and LCDR3 shown in SEQ ID NO: 76;

(5) HCDR1 shown in SEQ ID NO: 2, HCDR2 shown in SEQ ID NO: 17, HCDR3 shown in SEQ ID NO: 32, LCDR1 shown in SEQ ID NO: 47, LCDR2 shown in SEQ ID NO: 62 and LCDR3 shown in SEQ ID NO: 77;

(6) HCDR1 shown in SEQ ID NO: 3, HCDR2 shown in SEQ ID NO: 18, HCDR3 shown in SEQ ID NO: 33, LCDR1 shown in SEQ ID NO: 48, LCDR2 shown in SEQ ID NO: 63 and LCDR3 shown in SEQ ID NO: 78;

(7) HCDR1 shown in SEQ ID NO: 5, HCDR2 shown in SEQ ID NO: 20, HCDR3 shown in SEQ ID NO: 35, LCDR1 shown in SEQ ID NO: 50, LCDR2 shown in SEQ ID NO: 65 and LCDR3 shown in SEQ ID NO: 80;

(8) HCDR1 shown in SEQ ID NO: 6, HCDR2 shown in SEQ ID NO: 21, HCDR3 shown in SEQ ID NO: 36, LCDR1 shown in SEQ ID NO: 51, LCDR2 shown in SEQ ID NO: 66 and LCDR3 shown in SEQ ID NO: 81;

(9) HCDR1 shown in SEQ ID NO: 7, HCDR2 shown in SEQ ID NO: 22, HCDR3 shown in SEQ ID NO: 37, LCDR1 shown in SEQ ID NO: 52, LCDR2 shown in SEQ ID NO: 67 and LCDR3 shown in SEQ ID NO: 82;

(10) HCDR1 shown in SEQ ID NO: 8, HCDR2 shown in SEQ ID NO: 23, HCDR3 shown in SEQ ID NO: 38, LCDR1 shown in SEQ ID NO: 53, LCDR2 shown in SEQ ID NO: 68 and LCDR3 shown in SEQ ID NO: 83;

(11) HCDR1 shown in SEQ ID NO: 9, HCDR2 shown in SEQ ID NO: 24, HCDR3 shown in SEQ ID NO: 39, LCDR1 shown in SEQ ID NO: 54, LCDR2 shown in SEQ ID NO: 69 and LCDR3 shown in SEQ ID NO: 84;

(12) HCDR1 shown in SEQ ID NO: 10, HCDR2 shown in SEQ ID NO: 25, HCDR3 shown in SEQ ID NO: 40, LCDR1 shown in SEQ ID NO: 55, LCDR2 shown in SEQ ID NO: 70 and LCDR3 shown in SEQ ID NO: 85;

(13) HCDR1 shown in SEQ ID NO: 11, HCDR2 shown in SEQ ID NO: 26, HCDR3 shown in SEQ ID NO: 41, LCDR1 shown in SEQ ID NO: 56, LCDR2 shown in SEQ ID NO: 71 and LCDR3 shown in SEQ ID NO: 86;

(14) HCDR1 shown in SEQ ID NO: 12, HCDR2 shown in SEQ ID NO: 27, HCDR3 shown in SEQ ID NO: 42, LCDR 1 shown in SEQ ID NO: 57, LCDR2 shown in SEQ ID NO: 72 and LCDR3 shown in SEQ ID NO: 87; or

(15) HCDR1 shown in SEQ ID NO: 13, HCDR2 shown in SEQ ID NO: 28, HCDR3 shown in SEQ ID NO: 43, LCDR1 shown in SEQ ID NO: 58, LCDR2 shown in SEQ ID NO: 73 and LCDR3 shown in SEQ ID NO: 88.

2 . The antibody or the antigen-binding fragment thereof of claim 1 , wherein the amino acid sequence of the heavy chain variable region is selected from an amino acid sequence shown in SEQ ID NO: 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 or 105 or an amino acid sequence having at least 90% identity thereto.

3 . The antibody or the antigen-binding fragment thereof of claim 1 , wherein the amino acid sequence of the light chain variable region is selected from an amino acid sequence shown in SEQ ID NO: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 or 120 or an amino acid sequence having at least 90% identity thereto.

4 . The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody contains

(1) a heavy chain variable region shown in SEQ ID NO: 104 and a light chain variable region shown in SEQ ID NO: 119;

(2) a heavy chain variable region shown in SEQ ID NO: 94 and a light chain variable region shown in SEQ ID NO: 109;

(3) a heavy chain variable region shown in SEQ ID NO: 105 and a light chain variable region shown in SEQ ID NO: 120;

(4) a heavy chain variable region shown in SEQ ID NO: 91 and a light chain variable region shown in SEQ ID NO: 106;

(5) a heavy chain variable region shown in SEQ ID NO: 92 and a light chain variable region shown in SEQ ID NO: 107;

(6) a heavy chain variable region shown in SEQ ID NO: 93 and a light chain variable region shown in SEQ ID NO: 108;

(7) a heavy chain variable region shown in SEQ ID NO: 95 and a light chain variable region shown in SEQ ID NO: 110;

(8) a heavy chain variable region shown in SEQ ID NO: 96 and a light chain variable region shown in SEQ ID NO: 111;

(9) a heavy chain variable region shown in SEQ ID NO: 97 and a light chain variable region shown in SEQ ID NO: 112;

(10) a heavy chain variable region shown in SEQ ID NO: 98 and a light chain variable region shown in SEQ ID NO: 113;

(11) a heavy chain variable region shown in SEQ ID NO: 99 and a light chain variable region shown in SEQ ID NO: 114;

(12) a heavy chain variable region shown in SEQ ID NO: 100 and a light chain variable region shown in SEQ ID NO: 115;

(13) a heavy chain variable region shown in SEQ ID NO: 101 and a light chain variable region shown in SEQ ID NO: 116;

(14) a heavy chain variable region shown in SEQ ID NO: 102 and a light chain variable region shown in SEQ ID NO: 117; or

(15) a heavy chain variable region shown in SEQ ID NO: 103 and a light chain variable region shown in SEQ ID NO: 118.

5 . The antibody or the antigen-binding fragment thereof of claim 1 , specifically binding to a VHH domain.

6 . The antibody or the antigen-binding fragment thereof of claim 5 , wherein the VHH domain is a VHH domain of a camel-derived antibody.

7 . The antibody or the antigen-binding fragment thereof of claim 6 , wherein the camel-derived antibody is a single-domain antibody or a heavy-chain antibody derived from Camelus dromedarius, Camelus bactrianus, Vicugna pacos or Lama glama.

8 . The antibody or the antigen-binding fragment thereof of claim 5 , specifically binding to a VHH domain shown in SEQ ID NO: 241 or a VHH domain having at least 60% amino acid sequence identity to SEQ ID NO: 241.

9 . The antibody or the antigen-binding fragment thereof of claim 5 , binding to the VHH domain at a conformational epitope in a framework region.

10 . The antibody or the antigen-binding fragment thereof of claim 5 , specifically binding to a framework region of the VHH domain shown in SEQ ID NO: 241 or a framework region having at least 70% amino acid sequence identity to the framework region of the VHH domain shown in SEQ ID NO: 241.

11 . The antibody or the antigen-binding fragment thereof of claim 1 , selected from Fab, F(ab′) 2 , scFv, a chimeric antibody, a humanized antibody, a diabody and a multispecific antibody.

12 . One or more polynucleotides, encoding the antibody or the antigen-binding fragment thereof of claim 1 .

13 . One or more vectors, comprising the one or more polynucleotides of claim 12 .

14 . A host cell, comprising the one or more polynucleotides of claim 12 .

15 . A method for detecting a VHH domain, comprising adding the antibody or the antigen-binding fragment thereof of claim 1 to a sample that is known or suspected to contain the VHH domain and detecting a complex formed between the antibody or the antigen-binding fragment thereof and the VHH domain.

16 . A method for separating a VHH domain, comprising adding the antibody or the antigen-binding fragment thereof of claim 1 to a sample that is known or suspected to contain the VHH domain and separating a complex formed between the antibody or the antigen-binding fragment thereof and the VHH domain.

17 . The method of claim 15 , wherein the VHH domain is in a camel-derived antibody and/or a chimeric antigen receptor.

18 . The method of claim 17 , wherein the chimeric antigen receptor is on an immune cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2022
From: QIN, XIJIAN; SUN, LIWEI; WANG, WANYI; SONG, GUANGWEI
To: NANJING GENSCRIPT BIOTECH CO., LTD.
Reel/Frame 059017/0324 →
Priority Claims (1)
CN 201910922329.6 · Sep 27, 2019 · national
Continuity (1)
Related Publication 20220281997A1 · Sep 8, 2022
References Cited (20)
US 20190233519A1 · Zhang et al. · 2019 [cited by applicant]
CN 109843923A · 2019 [cited by applicant]
Vajdos et al. (J Mol Biol. Jul. 5, 2002;320(2):415-28). (Year: 2002). [cited by examiner]
Bedouelle et al. (FEBS J. Jan. 2006;273(1):34-46). (Year: 2006). [cited by examiner]
Brown et al. (J Immunol. May 1, 1996;156(9):3285-91). (Year: 1996). [cited by examiner]
Rudikoff et al. (Proc. Natl. Acad. Sci. USA, 79: 1979-1983, Mar. 1982). (Year: 1982). [cited by examiner]
Colman (Research in Immunology, 145:33-36, 1994). (Year: 1994). [cited by examiner]
Examiner prepared alignment of antibody Vh domains, 1 page, 2025. (Year: 2025). [cited by examiner]
Examiner prepared alignment of antibody VI domains, 1 page, 2025. (Year: 2025). [cited by examiner]
Examiner prepared alignment of Vhh domains, 1 page, 2025. (Year: 2025). [cited by examiner]
“MonoRabTM Rabbit Anti-Camelid VHH Antibody [iFluor488], MAb.,” GenScript, May 5, 2017 (May 5, 2017). [cited by applicant]
“Jackson ImmunoResearch: Jackson Alpaca Family-Nanobody VHH Newly Launched,” Xibao Biotechnology (Sep. 26, 2019). [cited by applicant]
“Accelerating Nanobody Production Using Polyclonal Anti-VHH Antibodies,” (Sep. 13, 2019). [cited by applicant]
International Search Report (Form PCT/ISA/210) for International Patent Application No. PCT/CN2020/118150, issued from the International Searching Authority, date of mailing Dec. 30, 2020, with English-language translat… [cited by applicant]
Written Opinion of the International Searching Authority (Form PCT/ISA/237) for International Patent Application No. PCT/CN2020/118150, issued from the International Searching Authority, date of mailing Dec. 30, 2020, w… [cited by applicant]
Katrin et al., “Conditional control of fluorescent protein degradation by an auxin-dependent nanobody,” Nature Communications 9(1): 1-13 (2018). [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” PNAS 79:1979-1983 (1982). [cited by applicant]
Winkler et al., “Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody,” J. Immunol. 165(8):4505-4514 (2000). [cited by applicant]
Chanier et al., “Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer,” Antibodies 8(1):1-21 (2019). [cited by applicant]
Jena et al., “Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials,” PLOS One 8(3): e57838 (2013). [cited by applicant]